

Supplemental Table 1. Paired specimen patient characteristics of in the talazoparib neoadjuvant feasibility study TiME subgroup

Age (years)	Median (range)	40 (32-55)
Race	White	5
	Black	4
	Hispanic	1
	Asian	1
Clinical stage ^a	I	2
	II	7
	III	2
Clinical nodal stage	N0	9
	N1	1
	N2-3	1
Hormone-receptor status	Positive	4
	Negative	7
<i>BRCA</i> Status	<i>BRCA1</i>	8
	<i>BRCA2</i>	3
Histology	Ductal	10
	Metaplastic	1
Grade	1	0
	2	1
	3	10
Percent decrease in tumor volume by ultrasound	Median (range)	87.6 (29.8 to 97.8)
Residual cancer burden	0	5
	I	3
	II	3
Pathologic complete response	Yes	5
	No	6

^aAnatomic Stage/Prognostic Groups AJCC 7th Edition.